Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Harvey RD"'
Autor:
Zhou X; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA. xiaofei.zhou@takeda.com., Vaishampayan U; Karmanos Cancer Institute, Detroit, MI, USA.; University of Michigan, Ann Arbor, MI, USA., Mahalingam D; Northwestern Medical Group, Chicago, IL, USA., Harvey RD; Emory University, Atlanta, GA, USA., Chung KY; Prisma Health Cancer Institute/ITOR, Greenville, SC, USA., Sedarati F; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Dong C; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Faller DV; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Venkatakrishnan K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; EMD Serono Research & Development Institute, Inc., MB, Billerica, USA., Gupta N; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2022 Oct; Vol. 40 (5), pp. 1042-1050. Date of Electronic Publication: 2022 Aug 06.
Autor:
Dowlati A; Department of Medicine Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA., Harvey RD; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA., Carvajal RD; Department of Medicine, Division of Hematology/Oncology, Columbia University, College of Physicians and Surgeons New York, New York, NY, USA., Hamid O; Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Cedars-Sinai Affiliate, Los Angeles, CA, USA., Klempner SJ; Department of Medicine and Oncology, Massachusetts General Hospital, Boston, MA, USA., Kauh JSW; Medical Oncology, Hutchison MediPharma Inc., Florham Park, NJ, USA., Peterson DA; Eli Lilly and Company, Indianapolis, IN, USA., Yu D; Eli Lilly and Company, Indianapolis, IN, USA., Chapman SC; Eli Lilly and Company, Windlesham, Surrey, UK., Szpurka AM; Eli Lilly and Company, Indianapolis, IN, USA., Carlsen M; Eli Lilly and Company, Indianapolis, IN, USA., Quinlan T; Eli Lilly and Company, Indianapolis, IN, USA., Wesolowski R; Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, 1310D Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA. Robert.Wesolowski@osumc.edu.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2021 Aug; Vol. 39 (4), pp. 1057-1071. Date of Electronic Publication: 2021 Feb 23.
Autor:
Martini DJ; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Liu Y; Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA., Shabto JM; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Lewis C; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Kline MR; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Collins H; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Akce M; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Kissick HT; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Carthon BC; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Shaib WL; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Alese OB; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Pillai RN; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Steuer CE; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Wu CS; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Lawson DH; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Kudchadkar RR; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Master VA; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., El-Rayes BF; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Ramalingam SS; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Owonikoko TK; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Harvey RD; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA.; Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA., Bilen MA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. mehmet.a.bilen@emory.edu.; Winship Cancer Institute of Emory University, Atlanta, GA, USA. mehmet.a.bilen@emory.edu.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2019 Dec; Vol. 37 (6), pp. 1198-1206. Date of Electronic Publication: 2019 Feb 06.
Autor:
Lockhart AC; Division of Medical Oncology, University of Miami/Sylvester Comprehensive Cancer Center, 1120 NW 14th Street, Suite 650L, Miami, FL, USA. aclockhart@med.miami.edu., Bauer TM; Drug Development, Sarah Cannon Research Institute/Tennessee Oncology PLLC., Nashville, TN, USA., Aggarwal C; Division of Hematology-Oncology, Department of Medicine, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, USA., Lee CB; Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Harvey RD; Departments of Hematology and Medical Oncology and Pharmacology, Emory University School of Medicine, Winship Cancer Institute of Emory University, Atlanta, GA, USA., Cohen RB; Department of Medicine, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, USA., Sedarati F; Oncology Clinical Research, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA., Nip TK; Biostatistics, Takeda Development Centre EU, London, UK., Faessel H; Quantitative Clinical Pharmacology, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA., Dash AB; Translational and Biomarker Research, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA., Dezube BJ; Oncology Clinical Research, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA., Faller DV; Oncology Clinical Research, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA., Dowlati A; Department of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2019 Feb; Vol. 37 (1), pp. 87-97. Date of Electronic Publication: 2018 May 21.